Table 12 Summary of human studies investigating antineoplastic effects of resistant starch
AuthorStudy subjectsType, dose and duration of RS treatmentEffect of RS
Van Muster et al314 healthy subjects45 g Hylon VII (32%) or 20 g RS low natural fibre↓Cell proliferation, ↑SCFA and butyrate, ↓bile acids
Grubben et al1523 patients with recently removed colonic adenomas45 g amylomaize (28 g RS)/day or 45 g maltodextrinCell proliferation NSD, ↑butyrate
Van Gorkom et al16111 sporadic adenoma patients30 g Hylon VII (19 g RS) or 30 g of placebo starchCell proliferation NSD
Wacker et al1712 healthy subjectsHylon VII (50.7–59.7 g/day) or low RS corn starchCell proliferation NSD, ↑DNA adducts, ↑SCFA
  • NSD, non-significant difference; RS, resistant starch; SCFA, short chain fatty acid.

  • ↑ indicates an increase; ↓ indicates a decrease.